No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly
CSC: The potential of AI in pharmaceuticals is being released and is expected to reshape the future landscape of medicine.
AI is expected to reshape the model of drug discovery and bring subtle yet continuous cost reduction and efficiency improvement to the pharmaceutical Industry, driving the rapid growth of AI pharmaceutical pipelines and markets, and being Bullish on the long-term development potential and prospects of the AI pharmaceutical Industry.
Chengdu Pilot: Announcement on the 2024 Annual Results Report of Chengdu Pilot Pharmaceutical Development Co., Ltd.
Chengdu Pilot Drug Development Co., Ltd. 2024 Annual Performance Report Announcement
Hitgen Inc. (688222.SH): The net income for the year 2024 is 50.9366 million yuan, an increase of 25.09% year-on-year.
On February 27, Gelonghui reported that Hitgen Inc. (688222.SH) disclosed its performance forecast for 2024. During the reporting period, the company achieved revenue of 426.9869 million yuan, a year-on-year increase of 14.99%; net income attributable to the parent company's owners was 50.9366 million yuan, a year-on-year increase of 25.09%; and net income attributable to the parent company's owners after deducting non-recurring gains and losses was 55.3698 million yuan, a year-on-year increase of 1,504.05%. During the reporting period, the commercial projects of the company's various technology platforms steadily advanced, and research projects progressed smoothly, contributing to the growth of main business revenue.
Time To Worry? Analysts Are Downgrading Their HitGen Inc. (SHSE:688222) Outlook